The rise of covalent proteolysis targeting chimeras.


Journal

Current opinion in chemical biology
ISSN: 1879-0402
Titre abrégé: Curr Opin Chem Biol
Pays: England
ID NLM: 9811312

Informations de publication

Date de publication:
06 2021
Historique:
received: 21 10 2020
revised: 05 12 2020
accepted: 20 12 2020
pubmed: 8 2 2021
medline: 8 9 2021
entrez: 7 2 2021
Statut: ppublish

Résumé

Targeted protein degradation offers several advantages over direct inhibition of protein activity and is gaining increasing interest in chemical biology and drug discovery. Proteolysis targeting chimeras (PROTACs) in particular are enjoying widespread application. However, PROTACs, which recruit an E3 ligase for degradation of a target protein, still suffer from certain challenges. These include a limited selection for E3 ligases on the one hand and the requirement for potent target binding on the other hand. Both issues restrict the target scope available for PROTACs. Degraders that covalently engage the target protein or the E3 ligase can potentially expand the pool of both targets and E3 ligases. Moreover, they may offer additional advantages by improving the kinetics of ternary complex formation or by endowing additional selectivity to the degrader. Here, we review the recent progress in the emerging field of covalent PROTACs.

Identifiants

pubmed: 33549806
pii: S1367-5931(20)30162-9
doi: 10.1016/j.cbpa.2020.12.003
pii:
doi:

Substances chimiques

Ligands 0
Piperidines 0
ibrutinib 1X70OSD4VX
Acrylamide 20R035KLCI
Ubiquitin-Protein Ligases EC 2.3.2.27
Proteasome Endopeptidase Complex EC 3.4.25.1
Adenine JAC85A2161

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

24-33

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Ronen Gabizon (R)

Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, 7610001, Israel. Electronic address: ronen.gabizon@weizmann.ac.il.

Nir London (N)

Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, 7610001, Israel. Electronic address: nir.london@weizmann.ac.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH